Many different designs of total hip arthroplasty (THA) with varying performance and cost are available. The identification of those which are the most cost-effective could allow significant cost-savings. We used an established Markov model to examine the cost effectiveness of five frequently used categories of THA which differed according to bearing surface and mode of fixation, using data from the National Joint Registry for England and Wales. Kaplan-Meier analyses of rates of revision for men and women were modelled with parametric distributions. Costs of devices were provided by the NHS Supply Chain and associated costs were taken from existing studies. Lifetime costs, lifetime quality-adjustedlife-years (QALYs) and the probability of a device being cost effective at a willingness to pay £20 000/QALY were included in the models.
Many different designs of total hip arthroplasty (THA) with varying performance and cost are available. The identification of those which are the most cost-effective could allow significant cost-savings. We used an established Markov model to examine the cost effectiveness of five frequently used categories of THA which differed according to bearing surface and mode of fixation, using data from the National Joint Registry for England and Wales. Kaplan-Meier analyses of rates of revision for men and women were modelled with parametric distributions. Costs of devices were provided by the NHS Supply Chain and associated costs were taken from existing studies. Lifetime costs, lifetime quality-adjustedlife-years (QALYs) and the probability of a device being cost effective at a willingness to pay £20 000/QALY were included in the models.
The differences in QALYs between different categories of implant were extremely small (< 0.0039 QALYs for men or women over the patient's lifetime) and differences in cost were also marginal (£2500 to £3000 in the same time period). As a result, the probability of any particular device being the most cost effective was very sensitive to small, plausible changes in quality of life estimates and cost.
Our results suggest that available evidence does not support recommending a particular device on cost effectiveness grounds alone. We would recommend that the choice of prosthesis should be determined by the rate of revision, local costs and the preferences of the surgeon and patient. Total hip arthroplasty (THA) is a commonly undertaken procedure which is both cost and clinically effective. 1 More than 80 000 are performed each year in the United Kingdom, mainly for osteoarthritis. 2 As the demand for THA grows, increasing attention is being paid to its cost-effectiveness and the choice between designs and modes of fixation.
At an average cost of about £6000, primary THA costs the NHS approximately £64 million per annum. 3 Assuming an estimated rate of revision of about 5% over the lifetime of 80 000 recipients and an average cost of revision of about £17 000, 3 failure adds about another £68 million over subsequent years. The UK National Institute for Health and Care Excellence (NICE) 4 has issued guidance (TA2 and TA44) which suggests that clinicians and manufacturers should aim to achieve a benchmark revision rate of < 10% over ten years. This has recently been reviewed and a new ten-year benchmark of 5% has been recommended (review of technology appraisal guidance 2 and 44). 1 Rates of revision are likely to depend, in part at least, on the bearing surfaces and mode of fixation. 5, 6 In the United Kingdom, over 100 different brands of prosthesis are available, manufactured by at least 20 companies, each of whom make individual purchasing arrangements with orthopaedic units. 7 Identification of the most cost-effective devices could inform decisions about the choice of prosthesis, potentially saving resources for deployment elsewhere. Based on UK Registry data, this study aims to examine and compare the costeffectiveness of frequently used combinations of components in THA, including the type of fixation and bearing surfaces.
Patients and Methods
After obtaining ethical approval, we sought individual patient data (IPD) from the National Joint Registry (NJR) for England and Wales for patients undergoing THA for osteoarthritis between April 2003 and December 2012. We focused on the most common types as it was impractical to examine all available combinations of components. We used an iterative cross-tabulation procedure to stratify the various combinations of components by usage.
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Variables included the material used for the bearing couple, and whether the components were cemented or cementless. We selected the four combinations with the highest recorded usage, and added one further combination because our clinical advisors indicated that it had recently become very popular.
We used a Markov multi-state model, which has been used in previous studies of the cost effectiveness of primary THA ( Fig. 1) to model the cost effectiveness of each combination. [8] [9] [10] [11] In this model, patients exist in one of four mutually exclusive states: successful primary THA; 8 revision surgery (patients can move into this state more than once but stay in this state for one annual cycle only); successful revision surgery; death (patients may enter this state both due to operative mortality or due to death from other causes).
Three sets of model inputs were used: yearly transition probability (the probability of converting from successful THA to 'revision surgery' or 'death'), costs associated with each state, and quality of life (QOL) utilities. 8 The parameters for the input into the models are summarised in Table I . [12] [13] [14] [15] [16] [17] Each cycle lasted one year. The probability of transition to death, beyond the first cycle, was based on data from the Office for National Statistics for appropriately aged men and women. 18 For the costing analysis, an NHS and Personal Social Services perspective was chosen. In line with current standard practice in the United Kingdom including the NICE guidelines for economic analysis, a 3.5% annual discount rate was applied for both costs and outcomes. 4 All costs are reported in 2012 British pounds sterling.
Probabilistic analyses were performed with 1000 iterations for each group of input parameters so as to capture uncertainties in the inputs of the model. 19 We used two different time horizons: ten years to take into account and capture the revision data we had, and a lifetime horizon to capture lifetime costs and consequences. The outputs from the model included mean quality-adjusted life years gained (QALYs), 19 mean costs, and the probability that a particular prosthesis was the most cost-effective option of those available at given levels of willingness to pay.
NJR data were used to derive estimates of the time to revision using Kaplan-Meier analyses. In order to model life-time revision, parametric distributions were fitted to Kaplan-Meier graphs using standard software (Stata version 11, Stata Corp., College Station, Texas) and these were used to extrapolate to a lifetime horizon. Goodness of fit was judged by eye and according to the Akaike information criterion and the Bayesian information criterion. In order to predict lifetime revision rates for 60, 70 and 80 year-old patients, we stratified NJR data by gender and controlled the parametric models for age. We explored the data using several parametric models (bathtub, lognormal, loglogistic, Gompertz and Weibull) and selected the model providing the best fit. Bathtub models were implemented with the user-written 'stgenreg' package in Stata. 20 Outcomes were measured in QALYs. QOL data were obtained from the database of patient-reported outcome measures (PROMs) for patients who had a THA between January 2009, when the collection of PROMs began in England, and December 2012.
14 EuroQol 5 Domain (EQ-5D) scores for successful primary and revision health states were used to reflect differences in age and gender. 21 The costs of the different prostheses were provided by the NHS supply chain. The mean cost of each combination was calculated using the list prices from each of the five most commonly-used suppliers in each category. The costs of a successful primary THA, revision procedure and successful revision procedure were taken from various sources within the literature (Table I) . [15] [16] [17] The cost of each health state included the cost of the operation, the prosthesis, the hospital ward and follow-up. [15] [16] [17] Where necessary, costs were inflated to current prices by applying the projected Health Services Cost Index (HSCI). 22 Sensitivity analyses included the following changes to model inputs: alternative QOL utility values drawn from a previous study of NJR data; 23 alternative costs of prostheses from the same study; 23 a combination of both of the above from the same study 23 and lifetime revision rates modelled using lognormal rather than bathtub distributions.
Results
The THA dataset held a total of 386 556 useable records for patients with osteoarthritis. Resurfacing records were excluded, as were those for conditions other than osteoarthritis or if the condition was ambiguous. The five frequently-used combinations of prosthesis accounted for 239 089 records (approximately 62% of osteoarthritis patients). The characteristics of these five mutually exclusive categories are summarised in Table II. Kaplan-Meier analyses of time to revision are shown in Figure 2 . This time differed according to the type of prosthesis and gender. The overall rates of revision were higher in men than women. In all categories, apart from category E (ceramic head (cemented stem) on cemented polyethylene cup (CeCoP)), the difference in rates by gender was statistically significant (p < 0.05) both with and without stratification for age (the un-stratified log rank p values were: 0.0000 for category A, 0.0058 for category B, 0.0405 for category C, 0.0151, for category D and 0.5337 for category E, respectively; the corresponding age stratified p-values were: 0.0000 (A), 0.0049 (B), 0.0353 (C), 0.0205 (D) and 0.6038 (E)). The distribution of age varied between categories, but was similar for men and women within each category The best fit to Kaplan-Meier data were provided by the bathtub model in virtually all cases. Lognormal models provided the next best fits. Bathtub models were therefore used for the base case analyses, and lognormal models were used in the analysis of sensitivity. Figure 3 summarises the rates of revision to 100 years of age predicted by the bathtub model.
Lifetime rates of revision were lowest for category E (CeCoP) and highest for category C (cementless ceramicon-ceramic (CeLCoC)), irrespective of gender and age. Projected revisions to 100 years of age for patients receiving cemented metal-on-polyethylene THA were less than half for those receiving CeLCoC prostheses. Table III summarises the base-case results for ten year and lifetime horizons for men and women aged 60, 70 and 80 years. Differences in accumulated QALYs between the types of prosthesis were small (Fig. 4) . The differences in the lifetime costs of different types of prosthesis were marginal, and were mainly determined by differences in the initial cost of the prostheses and in the subsequent rates of revision. Younger patients are likely to accumulate more revisions in their lifetime than older patients. Thus, lifetime costs for this group are more influenced by the probability of revision. As a result, the rate of revision is relatively more important in younger patients, while the cost of the initial THA is more important in older patients when determining which of the options is most costeffective (Figs 4 and 5) .
In a sensitivity analysis, we used alternative cost and QOL inputs from Pennington et al. 23 There were again small differences in cost effectiveness between different types of prosthesis, although the differences between prostheses were reduced compared with our study. No prosthesis had a > 45% chance of being the most cost effective of the alternatives. The outcome of this analysis suggests that our conclusions are robust to credible changes in cost and QOL inputs. Likewise, when the data were re-analysed using the lognormal rather than the bathtub model, outcomes were similar, again suggesting that the conclusions are robust.
Discussion
Our base-case analysis found that at a willingness to pay £20 000 per QALY a cemented prosthesis with metal-onpolyethylene or ceramic-on-polyethylene bearings (categories A and E) had the greatest probability of being cost effective for all groups of age and gender over a lifetime. However, the differences in QALYs between categories were extremely small and differences in mean costs were borderline, lying between only £2550 and £3000 over a lifetime for all comparisons, irrespective of age or gender. The small differences in QOL and costs between types of prosthesis suggest that the underlying NJR and PROMs data may not be suitably robust to perform this form of analysis. Our results differ from those recently reported by Pennington et al, 23 who compared cemented, cementless and hybrid THAs. They used linked NJR/hospital episode statistics/PROMs data, and reported that, in all groups except women aged 80 years, hybrid THAs were the most likely to be cost effective at the same threshold of willingness to pay as we used in our study. These differences may be explained by differences in methodology between the studies. They did not examine differences in the bearing surface as we did. They used six-month PROM data to quantify differences in QOL between patients with different types of prosthesis, extrapolating these across the lifetime of the study. As a result, while the differences between the QOL outcomes in the different THAs were small (between 1.6% and 2.4% of the measured utility value), the fact that they exerted an effect over the entire lifetime of each patient resulted in large differences in cumulative lifetime QALYs during their study period. In our study, we did not consider type of prosthesis to exert an effect on QOL beyond the first six months (which is the period covered by the PROM data), as we doubt the reliability of using a single point estimate at six months to reflect reality over an entire lifetime. There are also doubts about the completeness and reliability of the PROM data used. Multiple imputation was required by Pennington et al. 23 to complete missing data. The main strengths of this study are the increased granularity and clinical relevance of our approach in examining five frequently-used types of prosthesis, classified according to both bearing surface and mode of fixation. The selection of the five categories of prosthesis was conducted prior to all analyses of rates of revision. A further strength lies in the direct bathtub modelling, which avoids the problems seen in other similar analyses of combining two separate Weibull distributions. [23] [24] [25] Bathtub models have been used previously in studies of the cost effectiveness of THAs; they predict an initially decreasing hazard for revision (i.e., after primary surgery) followed by an increasing hazard as the prosthesis ages, and the quality of the patient's bone deteriorates. One of the main difficulties in conducting this research was that, although the NJR contains good individual patient data for time to revision after primary THA, other data are deficient or absent. Most importantly, no data are available on the level of activity of each patient, which may have a direct result on wear and the risk of revision. Body mass index, which may be considered a surrogate measure of activity, is incomplete in NJR data as noted by other authors. 26 A further limitation lies in the lack of QOL data over an extended period of time following primary THA, and also in the period leading up to, and following, revision. We were unable to model adverse effects which were not classified as revision, such as dislocation, which may necessitate a further hospital stay and costs, but which would not be detected using NJR data. However, we were able to weight the costs of revision according to a weighted average of the mean costs of all revision procedures. As with most other models of cost effectiveness, we assumed that after allowing for early death following surgery, there was no difference in mortality in association with different prostheses. However, three recent publications have used observational data to analyse rates of mortality in patients treated with different types of prosthesis. [27] [28] [29] One suggests higher mortality rates after cemented THA compared with cementless and resurfacing prostheses, 27 another found small differences between cemented and cementless THAs, but a large advantage for those treated with resurfacing prostheses, 28 while a third reported no significant differ- ences between cemented, cementless and hybrid THAs. 29 All authors acknowledged that a potential weakness in these studies was the limited ability to adjust for hidden covariates that may influence mortality. 30 New designs of THA can be introduced without the need for randomised studies demonstrating their superiority to existing devices. The few such studies that exist are too narrow in the scope of prostheses investigated, too low in power, and with too short a follow-up to give useful information. 31 It is therefore not surprising that economic studies rely on observational data.
Observational studies will always be susceptible to bias. Nevertheless, the high demand for THA, and its high use of resources, together with the large number of prostheses available on the market, mean that the rates of revision and cost effectiveness of different prostheses remain of considerable interest to patients, physicians, decision makers and the general public. 32 In our analyses, the differences in lifetimeaccumulated QALYs between the different types of prosthesis were very small. Differences in cost per QALY were only borderline. There are large uncertainties, particularly regarding the costs of prostheses and the estimates of lifetime QOL. On the basis of such small differences and such considerable uncertainties, it is difficult to make a comparison between the cost effectiveness of different types of prosthesis. Until better data dealing with costs and outcomes become available, it is difficult to justify the recommendation of one type of device over another on considerations of cost effectiveness alone. The choice of prosthesis should be determined by rates of revision, local costs and the preferences of both the surgeon and the patient.
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